The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels
References (0)
Cited by (40)
Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies
2021, Experimental NeurologyCitation Excerpt :BIIB093 is an intravenous (IV) formulation of glibenclamide (also known as glyburide). Glibenclamide is a sulfonylurea class of drugs that has been in clinical use as an oral hypoglycemic agent for the treatment of type 2 diabetes since 1969 (Feldman, 1985; Kurland et al., 2013; Marble, 1971) as it promotes the release of insulin by blocking pancreatic KATP [sulfonylurea receptor 1 (Sur1)-Kir6.2] channels (Kramer et al., 1995; Panten et al., 1996). Glibenclamide has received renewed attention in the last decade due to its neuroprotective effect in CNS injury, where its principal target is the transient receptor potential melastatin 4 (Trpm4), a non-slecetive cation channel that has been shown to be associated with Sur1 to form the Sur1-Trpm4 channels (Simard et al., 2006; Woo et al., 2013).
Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals
2015, Metabolism: Clinical and ExperimentalCitation Excerpt :Furthermore, Kramer et al. [32,33] have reported that individual sulfonylureas can interact with differing components of KATP channels. The same group has also demonstrated that glimepiride had a 3–4 fold lower binding affinity as compared to glyburide [32,33]. Although this study cannot identify the precise molecular mechanisms responsible for the differing physiologic effects of glimepiride and glyburide, the above studies certainly point to a plausible physiologic basis for our findings.
Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties
2012, Bioorganic and Medicinal Chemistry LettersPolymeric gene carrier for insulin secreting cells: Poly(L-lysine)-g- sulfonylurea for receptor mediated transfection
2005, Journal of Controlled ReleaseThe role of glimepiride in the effective management of Type 2 diabetes
2004, Journal of Diabetes and its ComplicationsInvestigation of structure-activity relationships in a series of glibenclamide analogues
2004, European Journal of Medicinal Chemistry